01—Abstract
Summary
Summary of the 10-K filed February 16, 2017. Cited figures are marked; the original filing is the authoritative source.
Zoetis Inc.'s 2016 10-K report highlights a strong year of growth and strategic execution.
The company, a global leader in animal health, reported total revenue of $4.89 billiona, a 3% increase year-over-year, driven by operational revenue growth of 5%. This growth was primarily fueled by key product performance, including Apoquel, and contributions from recent acquisitions like Pharmaq. The company continues to balance investment in new product development with optimizing its existing portfolio and operational efficiency, as evidenced by its ongoing operational efficiency program.
Zoetis operates in two key segments: the United States and International, with each contributing nearly half of the total revenue, showcasing a well-diversified geographic footprint. Financially, Zoetis demonstrated solid performance with net income attributable to Zoetis of $821 millionb, a significant increase from the prior year, supported by improved cost management and operational leverage.
The company also managed its debt effectively and continued its commitment to shareholder returns through dividends and share repurchases. Key risks identified include regulatory changes regarding antibiotic use in livestock, increased competition, and global economic conditions, all of which the company is actively managing.
02—Key points
Key Highlights
- Zoetis reported total revenue of $4.89 billion for fiscal year 2016, an increase of 3% from 2015, driven by strong operational revenue growth of 5%.
- The company's diverse product portfolio serves both livestock (59% of revenue) and companion animals (40% of revenue), with key product lines like ceftiofur and Apoquel driving significant revenue.
- Zoetis maintains a balanced geographic presence, with the United States (50% of revenue) and International markets (49% of revenue) contributing substantially to its top line.
- Net income attributable to Zoetis was $821 million, a significant increase from $339 million in 2015, reflecting improved profitability and operational efficiency.
- The company continued to invest in Research and Development, with R&D expenses of $376 million, focusing on both new product innovation and product lifecycle management.
- Zoetis is actively pursuing an operational efficiency program, which includes streamlining its product portfolio and optimizing its manufacturing and supply chain.
- The company is committed to shareholder returns, evidenced by consistent dividend payments and significant share repurchase activity authorized in December 2016.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2016filed February 16, 2017Financial Statements
FY2016 against FY2015
| Line item | FY2016FY2015 | Change |
|---|---|---|
| Revenue | $4.89B$4.76B | +2.6% |
| Cost of Revenue | $1.67B$1.74B | −4.1% |
| Gross Profit | $3.22B$3.03B | +6.4% |
| SG&A Expenses | $1.36B$1.53B | −11.0% |
| Interest Expense | $166.00M$124.00M | +33.9% |
| Net Income | $819.00M$339.00M | +141.6% |
| EPS (Basic) | $1.66$0.68 | +144.1% |
| EPS (Diluted) | $1.65$0.68 | +142.6% |
| Shares Outstanding (Basic) | 495.71M499.71M | −0.8% |
| Shares Outstanding (Diluted) | 498.23M502.02M | −0.8% |
05—Questions
Frequently Asked Questions
What was Zoetis's financial performance in 2016?
In 2016, Zoetis reported total revenue of $4.89 billion, a 3% increase from the previous year, with operational revenue growth of 5%. Net income attributable to Zoetis was $821 million. The company's performance was driven by strong sales in both its U.S. and International segments, particularly in companion animal products like Apoquel, and strategic acquisitions.
What are the main drivers of Zoetis's revenue growth?
Revenue growth is driven by a diversified product portfolio across livestock and companion animals. Key drivers include new product launches, continued performance of established brands (like Apoquel and the ceftiofur line), expansion into emerging markets, and product lifecycle innovation. Acquisitions, such as Pharmaq, also contribute to growth.
What are the primary risks facing Zoetis?
Key risks identified in the filing include potential restrictions on antibacterial use in food-producing animals, adverse public perception regarding food safety, increased regulation in the livestock industry, disease outbreaks, customer and distributor consolidation impacting pricing, weather conditions, global economic instability, and intense competition from both established and emerging players. Intellectual property protection and regulatory compliance are also critical.
How is Zoetis managing its operational efficiency?
Zoetis is implementing a comprehensive operational efficiency program focused on reducing product portfolio complexity, optimizing its selling approach, reducing its presence in certain countries, and divesting or exiting manufacturing sites. This program also involves workforce reductions to improve efficiency and cost structure.
What is Zoetis's approach to research and development?
Zoetis invests significantly in R&D, with a focus on both developing new chemical and biological entities and on product lifecycle innovation. This involves leveraging existing products by developing new claims for additional species, creating more convenient formulations, expanding into new markets, and investing in diagnostics and genetics research.
06—Continue